A reverse transcription loop-mediated isothermal amplification method to quantify multiple HIV subtypes

A rapid, quantitative point-of-care diagnostics method for viral load detection of HIV-1 clades A, B, C, D, and G

HIV infection remains an international health crisis, where it is especially acute in sub-Saharan Africa, despite the development of antiretroviral therapy.  High sensitivity, point-of-care clinical diagnostic tests for detecting and quantifying HIV viral load are lacking in development, particularly for resource-limited settings.

Existing technologies are immunoassay-based, which are not quantitative and do not allow for early detection prior to seroconversion or in neonates.  Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) amplifies cDNA. The amplicons can be detected by various methods, including intercalating fluorescent dye. 

Solution:

Researchers in the Bushman and Bau labs have improved existing HIV RT-LAMP assays to detect HIV subtypes A, B, C, D, and G, of which A and C are prevalent in Africa and India.  A bioinformatics study identified highly conserved sequences within the HIV genome, followed by the design and optimization of primers, targeting the HIV integrase coding region.  The work culminated in a rapid quantitative assay, with clinical samples currently being tested. 

The fluorescence-based DNA detection time is less than 20 minutes for amplifying more than 5,000 copies of nucleic acid.  In combination with a microfluidic diagnostic chip, a smart cup, consisting of a Thermos cup, a 3D printed cup lid, chip holder, and smartphone holder, designed by the Bau lab can be employed to detect the amplified nucleic acids in a minimally-instrumented format.

Advantages:

  • Low-cost with minimal equipment needed
  • Rapid process with actionable time scale
  • Quantitative measurement of viral load/RNA copy numbers
  • Early detection prior to seroconversion
  • Suitable for use in resource poor settings, in the clinic, and at home

Applications:

  • Monitor viral load in response to treatment
  • Detection of infection in neonates against background of maternal antibody
  • Combine with point-of-care plasma separation device developed by Bau lab
  • Use in resource-poor regions without trained staff, laboratory facilities, or electricity
  • Applicable for incorporation within multiplexed assays to detect co-infections

Example time course assay for fluorescence-based detection of HIV subtypes A and B using developed RT-LAMP primers. In (A), view of smart cup for minimally-instrumented, point-of-care molecular diagnostics, and in (B), a photograph of the smart cup equipped with smartphone and inset of integrated microfluidic chip with isothermal amplification reactors for nucleic acid extraction and amplification.

Stage of Development:

In vitro and clinical sample testing

Intellectual Property:

Reference Media:

Desired Partnerships:

 

  • License
  • Co-development

Patent Information:

Contact

Joshua Jeanson

Senior Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania

INVENTORS

Keywords

Docket # 15-7292